# GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies

> **NCT03214666** · PHASE1,PHASE2 · TERMINATED · sponsor: **GT Biopharma, Inc.** · enrollment: 12 (actual)

## Conditions studied

- High-risk Myelodysplastic Syndromes
- Acute Myelogenous Leukemia
- Systemic Mastocytosis
- Mast Cell Leukemia

## Interventions

- **DRUG:** GTB-3550 TriKE® Phase I
- **DRUG:** GTB-3550 TriKE® Phase II

## Key facts

- **NCT ID:** NCT03214666
- **Lead sponsor:** GT Biopharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-01
- **Primary completion:** 2021-08-02
- **Final completion:** 2021-09-29
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Development of GTB-3550 halted due to development of the second generation camelid nanobody TriKE drug product, GTB-3650.
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03214666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03214666, "GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03214666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*